Metalloproteinase 9 as a Biomarker of Progressive Multifocal Leukoencephalopathy Development in Multiple Sclerosis Patients Receiving Natalizumab

被引：1
|
作者：
Zahednasab, Hamid [1 ]
Harirchian, Mohammad Hossein [2 ]
Karampoor, Sajad [3 ]
Keyvani, Hossein [3 ]
机构：
[1] Univ Tehran, Inst Biochem & Biophys, Tehran, Iran
[2] Univ Tehran Med Sci, Imam Khomeini Hosp, Dept Neurol, Iranian Ctr Neurol Res, Tehran, Iran
[3] Iran Univ Med Sci, Sch Med, Dept Virol, Tehran, Iran
来源：
ANNALS OF NEUROLOGY | 2017年 / 82卷 / 04期
关键词：
D O I：
10.1002/ana.25037
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：647 / 647
页数：1
相关论文
共 50 条
  • [41] Natalizumab-Associated Progressive Multifocal Leukoencephalopathy in a Patient With Multiple Sclerosis: A Postmortem Study
    Wuethrich, Christian
    Popescu, Bogdan F. Gh
    Gheuens, Sarah
    Marvi, Michael
    Ziman, Ronald
    Denq, Stephen Pojen
    Tham, Mylyne
    Norton, Elizabeth
    Parisi, Joseph E.
    Dang, Xin
    Lucchinetti, Claudia F.
    Koralnik, Igor J.
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2013, 72 (11): : 1043 - 1051
  • [42] Risk of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patient Treated With Natalizumab: A Systematic Review
    Vivekanandan, Govinathan
    Abubacker, Ansha P.
    Myneni, Revathi
    Chawla, Harsh, V
    Iqbal, Aimen
    Grewal, Amit
    Ndakotsu, Andrew
    Khan, Safeera
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (04)
  • [43] Multiple sclerosis treatment strategy after natalizumab-associated progressive multifocal leukoencephalopathy
    Waheed, Rasha
    Warrier, Lakshmi
    Ouyang, Bichun
    Ko, Michael
    Stefoski, Dusan
    Koralnik, Igor
    Morales, Fabian Sierra
    JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2018, 13 : S90 - S90
  • [44] Multiple sclerosis treatment strategy after natalizumab-associated progressive multifocal leukoencephalopathy
    Waheed, Rasha
    Warrier, Lakshmi
    Ouyang, Bichun
    Ko, Michael
    Stefoski, Dusan
    Koralnik, Igor
    Morales, Fabian Sierra
    JOURNAL OF NEUROVIROLOGY, 2018, 24 : S90 - S90
  • [45] Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy
    Yousry, TA
    Major, EO
    Ryschkewitsch, C
    Fahle, G
    Fischer, S
    Hou, J
    Curfman, B
    Miszkiel, K
    Mueller-Lenke, N
    Sanchez, E
    Barkhof, F
    Radue, EW
    Jager, HR
    Clifford, DB
    NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (09): : 924 - 933
  • [46] Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients
    Rossi, Francesca
    Newsome, Scott D.
    Viscidi, Raphael
    MOLECULAR AND CELLULAR PROBES, 2015, 29 (01) : 54 - 62
  • [47] NATALIZUMAB AND THE RISK OF PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
    Aschenbrenner, Diane S.
    AMERICAN JOURNAL OF NURSING, 2011, 111 (08) : 23 - 23
  • [48] Review of progressive multifocal leukoencephalopathy and natalizumab
    Aksamit, Allen J.
    NEUROLOGIST, 2006, 12 (06) : 293 - 298
  • [49] Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis
    Herold, Tina Rike
    Jakl, Veronika
    Graser, Anno
    Eibl-Lindner, Kirsten
    CLINICAL OPHTHALMOLOGY, 2012, 6 : 1131 - 1133
  • [50] Lessons Learned From Fatal Progressive Multifocal Leukoencephalopathy in a Patient With Multiple Sclerosis Treated With Natalizumab
    Boster, Aaron L.
    Nicholas, Jacqueline A.
    Topalli, Ilir
    Kisanuki, Yaz Y.
    Pei, Wei
    Morgan-Followell, Bethanie
    Kirsch, Claudia F.
    Racke, Michael K.
    Pitt, David
    JAMA NEUROLOGY, 2013, 70 (03) : 398 - 402
12345